Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Characterization of the single-cell expression profile and immune status of replication repair deficient glioma
EF 2020-21
Résumé
Cells must replicate their DNA to divide and grow. To protect the integrity of the genome, the cell has two systems which prevent mutations during each replication cycle. The first is the ability of proteins that replicate DNA (POLD/E) to recognize when they have made a mistake and repair it. The second is a complex of mismatch repair (MMR) proteins which correct mistakes that have been missed by the first system. A significant portion of pediatric gliomas have replication repair deficiency (RRD) caused by errors in these systems. RRD gliomas are aggressive and respond poorly to conventional treatments. Recent work has shown that immunotherapy, drugs which activate the patient's immune system to attack their own tumour, is effective in more than 30% of RRD gliomas. However, tumour response to immunotherapy is variable and depends on the specific mutations which cause RRD. Our lab has identified three subtypes of RRD glioma which are associated with high, variable and low response to immunotherapy: MMR and POLE mutation, MMR and IDH1 mutation, and MMR mutation alone. This project aims to discover how these subtypes of RRD gliomas develop and how they interact with immune cells. We will use single cell RNA sequencing, a technique which tells us which genes are being expressed by each cell inside the tumor. We will compare the expression profile of tumour cells to the profile of normal cells during brain development to determine the type of cell that led to this cancer. We will also probe the types, quantities and activation states of immune cells to understand why some are able to kill the tumour and others are not. This work will allow us to create more accurate mouse models to study these cancers and develop better combination treatments for RRD glioma.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
449812
Name
Fernandez Nicholas R
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of the single-cell expression profile and immune status of replication repair deficient glioma
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Initiation; Glioma; Hypermutation; Immune Microenvironment; Mismatch Repair; Replication Repair Deficiency; Single Cell Sequencing; Tutor Development
Abstract
Cells must replicate their DNA to divide and grow. To protect the integrity of the genome, the cell has two systems which prevent mutations during each replication cycle. The first is the ability of proteins that replicate DNA (POLD/E) to recognize when they have made a mistake and repair it. The second is a complex of mismatch repair (MMR) proteins which correct mistakes that have been missed by the first system. A significant portion of pediatric gliomas have replication repair deficiency (RRD) caused by errors in these systems. RRD gliomas are aggressive and respond poorly to conventional treatments. Recent work has shown that immunotherapy, drugs which activate the patient's immune system to attack their own tumour, is effective in more than 30% of RRD gliomas. However, tumour response to immunotherapy is variable and depends on the specific mutations which cause RRD. Our lab has identified three subtypes of RRD glioma which are associated with high, variable and low response to immunotherapy: MMR and POLE mutation, MMR and IDH1 mutation, and MMR mutation alone. This project aims to discover how these subtypes of RRD gliomas develop and how they interact with immune cells. We will use single cell RNA sequencing, a technique which tells us which genes are being expressed by each cell inside the tumor. We will compare the expression profile of tumour cells to the profile of normal cells during brain development to determine the type of cell that led to this cancer. We will also probe the types, quantities and activation states of immune cells to understand why some are able to kill the tumour and others are not. This work will allow us to create more accurate mouse models to study these cancers and develop better combination treatments for RRD glioma.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fernandez, Nicholas R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~